Tyra Biosciences
Developer of oral FGFR-targeted medicines for urothelial cancers and achondroplasia.
$24.94
After-hours close−0.05 (−0.22%)
At close$25.00(−4.34%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 117.95%Insiders 26.51%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 59.66M · Float 44.33M · 74.3% free float
Institutions13F, as of Jun 30, 2026
177 holders · 70.37M shares · 36 new positions · 111 increased · 43 reduced · 25 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 12.20M | 20.45% | 0 | Aug 14, 2026 |
| FMR LLC | 8.92M | 14.95% | +1.17M | Aug 13, 2026 |
| Jupiter Topco LLC | 4.35M | 7.30% | +4.35Mnew | Aug 14, 2026 |
| Alta Partners Management Company, L.P. | 3.82M | 6.41% | 0 | Jul 22, 2026 |
| Nextech Invest, Ltd. | 3.55M | 5.96% | −502.3K | Aug 14, 2026 |
| TCG Crossover Management, LLC | 3.25M | 5.45% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 3.03M | 5.08% | +814.0K | Aug 7, 2026 |
| Price T Rowe Associates Inc /MD/ | 2.78M | 4.66% | +1.80M | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| RA Capital Management, L.P.incl. Peter Kolchinsky, Rajeev Shah +1 more | 21.20% | 12.27M | 13D | Mar 6, 2026 ↗ |
| FMR LLC | 14.40% | 7.75M | 13G | Apr 7, 2026 ↗ |
| Janus Henderson Group PLC | 7.20% | 3.89M | 13G | May 15, 2026 ↗ |
| TCG Crossover GP I, LLC | 5.70% | 2.90M | 13G | Mar 6, 2025 ↗ |
| Commodore Capital LP | 5.20% | 2.75M | 13G | May 14, 2025 ↗ |
| BlackRock, Inc. | 5.00% | 2.98M | 13G | Jul 30, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | director, 10 percent owner: | 10.26M | 17.20% | Jun 16, 2025 |
| Robert J. More | director | 3.82M | 6.41% | Dec 19, 2025 |
| Todd Harris | director, officer: President and CEO | 1.44M | 2.41% | May 7, 2026 |
| Daniel Bensen | officer: Chief Discovery Officer | 147.0K | 0.25% | Feb 13, 2026 |
| Yuliya Rueb | officer: Vice President, Finance (PAO) | 43.4K | 0.07% | May 7, 2026 |
| Alan Fuhrman | officer: Chief Financial Officer | 36.2K | 0.06% | May 7, 2026 |
| Gilla Kaplan | director | 28.2K | 0.05% | Mar 27, 2026 |
| Douglas J. Warner | officer: Chief Medical Officer | 25.0K | 0.04% | May 7, 2026 |
| Bhavesh Ashar | officer: Chief Operating Officer | 15.0K | 0.03% | May 7, 2026 |
4 ten-percent owners hold 5.18M shares by Form 4 — the 13D/G table above shows those stakes, the figure above counts officers and directors only · 10 people have not refiled in the last 18 months (6.00M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Mar 25, 2026 | Gilla Kaplandirector | Sale | 14,295 | $36.97 | 28,231 |
| Feb 12, 2026 | Daniel Bensenofficer: Chief Discovery Officer | Sale · 2 lots | 8,000 | $32.87 | 146,981 |
| Jan 12, 2026 | Daniel Bensenofficer: Chief Discovery Officer | Sale · 2 lots | 8,000 | $28.52 | 154,981 |
| Dec 19, 2025 | Robert J. Moredirector | Sale | 10,000 | $25.00 | 3,823,425 |
| Dec 12, 2025 | Daniel Bensenofficer: Chief Discovery Officer | Sale | 8,000 | $22.64 | 162,981 |
| Nov 21, 2025 | Robert J. Moredirector | Sale | 246,871 | $20.25 | 3,833,425 |
| Nov 19, 2025 | Daniel Bensenofficer: Chief Operating Officer | Sale | 49,956 | $16.32 | 170,981 |
| Nov 18, 2025 | Daniel Bensenofficer: Chief Operating Officer | Sale | 75,633 | $16.07 | 220,937 |
| Nov 17, 2025 | Daniel Bensenofficer: Chief Operating Officer | Sale · 2 lots | 20,072 | $16.18 | 296,570 |
| Nov 14, 2025 | Daniel Bensenofficer: Chief Operating Officer | Sale | 110,228 | $16.02 | 316,642 |
CongressHouse and Senate disclosures
Not reported.